Biotechnology Contract Manufacturing Market is predicted to reach USD 34.8 billion at a CAGR of 8.80% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Biotechnology Contract Manufacturing Market”.

The Biotechnology Contract Manufacturing market is estimated to register a CAGR of 8.80% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global biotechnology contract manufacturing market— Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Catalent, Inc. (US), Samsung Biologics (South Korea), WuXi Biologics (China), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holding Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), AGC, Inc. (Japan), Merck KgaA (Germany).

Market Highlights

The global biotechnology contract manufacturing market is expected to register a CAGR of 8.80% during the forecast period and is estimated to reach USD 34.8 billion by 2032.

The rising demand for cell and gene therapies, especially in developed and developing economies, will further create lucrative market growth opportunities. As advancements in biotechnology continue to expand the possibilities for personalized medicine and targeted treatments, the need for contract manufacturing services to scale up production efficiently becomes critical. Thus, the rising demand for cell and gene therapies directly fuels growth in the biotechnology contract manufacturing market.

Access Full Report @ https://www.marketresearchfuture.com/reports/biotechnology-contract-manufacturing-market-21957

Segment Analysis

The global biotechnology contract manufacturing market has been segmented based on service, type, scale of operation, source, molecule, and therapeutic area.

On the basis of service, the market is segmented into manufacturing, formulation & fill-finish, packaging & labelling, and other services. The manufacturing segment was attributed to holding the largest market share in 2023. The manufacture of biotechnological goods is outsourced and covers a range of phases from early development to commercialization. Contract manufacturing for biotechnology enables scalable and affordable production options for biologics, pharmaceuticals, and other bio-based goods, spurring innovation and market growth.

Based on type, the global biotechnology contract manufacturing market has been segmented into biologic drug substance manufacturing and biologic drug product manufacturing. The biologic drug substance manufacturing segment was expected to hold the largest market share in 2023. It concerns businesses that are involved in extensive production processes, frequently involving sizable amounts of biopharmaceuticals or biotechnological goods. These organizations usually function on a commercial basis, catering to large markets and frequently employing a substantial production infrastructure to effectively satisfy demand.

Based on the scale of operation, the global biotechnology contract manufacturing market has been segmented into commercial operations and clinical operations. The commercial operations segment was expected to hold the largest market share in 2023. It concerns businesses that are involved in extensive production processes, frequently involving sizable amounts of biopharmaceuticals or biotechnological goods. These organizations usually function on a commercial basis, catering to large markets and frequently employing a substantial production infrastructure to effectively satisfy demand.

Based on the source, the global biotechnology contract manufacturing market has been segmented into mammalian expression systems and non-mammalian expression systems. The mammalian expression systems segment was expected to hold the largest market share in 2023. The advantages of using mammalian expression methods include correct protein folding and post-translational modifications, which are essential for creating complex biologics. As a result, they continue to be the go-to option for producing a variety of biopharmaceutical goods.

Based on the molecule, the global biotechnology contract manufacturing market has been segmented into monoclonal antibodies, cell therapy & gene therapy, antibody-drug conjugates (ADCs), vaccines, therapeutic peptides & proteins, and other molecule types. The monoclonal antibodies segment was expected to hold the largest market share in 2023. Because they are widely used to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases, they account for a sizeable percentage of this market. The expansion of this market is driven by developments in biotechnology and the growing pipeline of treatments based on monoclonal antibodies.

Based on therapeutic area, the global biotechnology contract manufacturing market has been segmented into oncology, autoimmune diseases, cardiovascular diseases, metabolic diseases, infectious diseases, neurology and other therapeutic areas. The oncology segment was expected to hold the largest market share in 2023. Oncology contract manufacturing services are expanding significantly because of the rising need for personalized medicine and cutting-edge medicines. The significance of biotechnology contract manufacturing in providing creative ways to fight cancer is emphasized in this part.

Regional Analysis

The global biotechnology contract manufacturing market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The European biotechnology contract manufacturing market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The biotechnology contract manufacturing market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World biotechnology contract manufacturing market comprises the Middle East, Africa, and Latin America.

The largest market share for biotechnology contract manufacturing was maintained by the North American regional sector. The region hosts prominent biopharmaceutical companies outsourcing manufacturing services due to the cost-efficiency and expertise offered by contract manufacturers. Moreover, strategic collaborations and investments further bolster market expansion. With a focus on quality assurance and compliance, advanced infrastructure, technological innovation, and a strong regulatory framework, North America continues its development.

Moreover, the European market has been persistently growing over the forecast period. The demand for biotechnology contract manufacturing is driven by advanced healthcare infrastructure and a supportive regulatory environment. With increasing investment in biopharmaceuticals and a strong emphasis on innovation, Europe is expected to remain a prominent hub for biotechnology contract manufacturing services, catering to both domestic and international markets.

Additionally, due to the increasing investments in biotechnology, favorable regulatory environment, and availability of skilled labor, Asia Pacific is anticipated to experience the quickest growth over the forecast period. Additionally, countries are emerging as key hubs for contract manufacturing services in the biotechnology sector, driven by their robust infrastructure and cost advantages, further boosting market growth in the region.

Furthermore, the rest of the world's biotechnology contract manufacturing market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the increasing investments in healthcare infrastructure, and rising demand for biopharmaceuticals are propelling market growth. Additionally, collaborations between local and international biotech firms are further bolstering the region's contract manufacturing capabilities.

Key Findings of the Study

• The global biotechnology contract manufacturing market is expected to reach USD 34.8 billion by 2032, at a CAGR of 8.80% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the increasing investment in biopharmaceuticals and a strong emphasis on innovation.


• Based on the therapeutic area, the oncology segment was attributed to holding the largest market in 2023, with an approximate market share of 45–65%.


• Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Catalent, Inc. (US), Samsung Biologics (South Korea), WuXi Biologics (China), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holding Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), AGC, Inc. (Japan), and Merck KgaA (Germany) are the key market players.